The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

by Barry M Brenner, Mark E Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, William F Keane, Kiyoshi Kurokawa, Janet B McGill, William E Mitch, Hans Henrik Parving, Guiseppe Remuzzi, Arthur B Ribeiro, Mark D Schluchter, Duane Snavely, Zhongxin Zhang, Roger Simpson, Denise Ramjit, Shahnaz Shahinfar, RENAAL Study Investigators
Published 2000-12-01